Market Overview

UPDATE: Goldman Sachs Initiates Zoetis at Neutral; Upside Limited From Current Valuation

Related ZTS
Top Research Reports for UnitedHealth, Netflix & Pepsi
Celgene (CELG) Reports Data on Lupus Drug in Phase II Trial
Hermes Investment Management Ltd Buys Alibaba Group Holding, The Travelers Inc, TJX Inc, Sells ... (GuruFocus)

Goldman Sachs initiated coverage on Zoetis (NYSE: ZTS) with an Overweight rating and a $33.00 price target.

Goldman Sachs analyst Jami Rubin noted, "ZTS is the largest and only independently traded animal health company, with revenues of over $4.0 bn. We anticipate powerful macro trends in livestock and companion animals to provide tailwinds for sustained top line growth in the 5-7% range, with margin expansion yielding earnings growth in the upper teens through 2014, and low double-digit/high single-digit EPS growth thereafter. As a pure play animal health business, ZTS represents a scarce asset within our healthcare universe; however, as the stock currently trades at 23.5x 2013E we see limited upside from here."

Zoetis closed at $33.82 on Tuesday.

Latest Ratings for ZTS

Jul 2017Deutsche BankMaintainsBuy
Jun 2017Cantor FitzgeraldInitiates Coverage OnOverweight
Jun 2017BMO CapitalDowngradesOutperformMarket Perform

View More Analyst Ratings for ZTS
View the Latest Analyst Ratings

Posted-In: Goldman SachsAnalyst Color Initiation Analyst Ratings


Related Articles (ZTS)

View Comments and Join the Discussion!